Discovering breakthroughs in the life sciences, and doing it in a federally-compliant manner, can be a very lucrative business. At Vitality, over the past several years we’ve been focused especially on the use of cannabinoids for treating gastrointestinal conditions and their use as an alternative to opiate painkillers.

Regardless of whether we are studying IBD (Crohn’s & colitis), opioid dependence, autism, cancer, PTSD, refractory pain, or other conditions, the patient is always the focal point. A program isn’t worth pursuing if we’re not able to reach these patients and to have the potential to deliver a dramatic improvement over the existing standard-of-care.

With that focus in mind, we present to you Vitality’s two primary life science programs today:

Cannabosides: A New Class of Cannabinoid Pharmaceuticals

Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract.

Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream. Currently, high concentrations of psychoactive THC in the brain limit the dose of cannabinoids that can be used elsewhere in the body for treatment of pain and inflammation.

Read More

Vitality Healthtech: An Innovative Specialty Care Operation Harnessing Cannabinoids for Opiate Reduction

Through Vitality Healthtech, Inc., a wholly-owned subsidiary, Vitality has commenced healthcare operations in the United States designed to combat the opiate epidemic through use of cannabinoids. By targeting treatment to the estimated 10 million Americans that currently use opioids for chronic non-cancer pain, Vitality intends to help implement treatment regimens in a federally-compliant manner that will enable them to rapidly wean or taper off use of opiate painkillers.

The opioid-sparing effects of cannabinoids are well known, as studies have shown that the effective dose of morphine is 3.6 times lower when used with THC (Nielsen 2017). Additionally, self-reported patient surveys have shown that 97% of pain patients strongly agreed or agreed that they were able to decrease the amount of opioids used for pain with cannabinoids (n=828, Reiman 2017).

Read More
A program isn't worth pursuing if we're not able to reach these patients and to have the potential to deliver a dramatic improvement over the existing standard-of-care.